Bekinda is an irritable bowel syndrome with diarrhea treatment.
Here’s what you should know.
1. Researchers are conducting a randomized, double-blind, placebo-controlled phase II study evaluating Bekinda’s safety and efficacy in 127 patients with IBS-D.
2. Researchers enrolled patients in a randomized 60 to 40 ratio to receive either Bekinda or a placebo treatment, once-daily for eight weeks. Researchers are measuring stool consistency as compared to baseline.
3. RedHill expects results in the third quarter of fiscal year 2017. RedHill is also conducting a similar study with Bekinda 24 mg. The company expects results for that study in the second quarter of fiscal year 2017 second quarter.
More articles on gastroenterology:
Gastro Health acquires Gastroenterology Consultants: 4 key notes
GI leader to know: Dr. Adedayo Mokuolu of Desert Gastroenterology Associates
Tenapanor provides ‘compelling’ symptom relief in phase IIb trial: 3 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
